2-(1-苄基-4-哌啶)乙腈 | 78056-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(1-苄基-4-哌啶)乙腈
• 英文名称: 1-(phenylmethyl)-4-piperidineacetonitrile
• 英文别名: 2-(1-benzyl-4-piperidinyl)acetonitrile；2-(1-benzylpiperidin-4-yl)acetonitrile；(1-benzylpiperidin-4-yl)acetonitrile；1-(2-cyanoethyl)-4-benzylpiperidine；1-benzylpiperidine-4-acetonitrile
• CAS: 78056-67-4
• 化学式: C₁₄H₁₈N₂
• 分子量: 214.31
• InChiKey: ZKOHFVJCKMHYSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

SDS

Name:	1-Benzyl-4-Piperidineacetonitrile 97% Material Safety Data Sheet
Synonym:	None known
CAS:	78056-67-4

Section 1 - Chemical Product MSDS Name:1-Benzyl-4-Piperidineacetonitrile 97% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
78056-67-4	1-Benzyl-4-Piperidineacetonitrile	97	278-822-6

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Containers may explode when heated.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Cool containers with flooding quantities of water until well after fire is out. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Avoid runoff into storm sewers and ditches which lead to waterways.
Clean up spills immediately, observing precautions in the Protective Equipment section. Remove all sources of ignition. Absorb spill using an absorbent, non-combustible material such as earth, sand, or vermiculite. Do not use combustible materials such as sawdust.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 78056-67-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear slight brown
Odor: benzene-like
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 109 deg C (> 228.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.013
Molecular Formula: C14H18N2
Molecular Weight: 214.31

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, ignition sources, strong oxidants.
Incompatibilities with Other Materials:
Strong bases, strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 78056-67-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Benzyl-4-Piperidineacetonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 78056-67-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 78056-67-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 78056-67-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(1-苄基-4-哌啶)乙腈 在 盐酸羟胺 、 sodium 作用下， 以 甲醇 为溶剂， 反应 13.0h， 以66.66%的产率得到2-(1-benzyl-piperidin-4-yl)-N-hydroxy-acetamidine
  参考文献：
  名称：

  [EN] OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE
  [FR] COMPOSÉS OXADIAZOLE, LEUR PRÉPARATION ET LEUR UTILISATION

  摘要：

  本发明涉及氧代唑化合物的所有立体异构体和互变异构体形式以及它们在所有比例的混合物中；以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多形态。该发明还涉及制备氧代唑化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物可用于治疗癌症，特别是慢性髓样白血病（CML）。本发明还提供了一种治疗癌症的方法，即通过向需要的哺乳动物投予所述化合物或其药物组合物的治疗有效剂量。

  公开号：

  WO2011104680A1
• 作为产物：
  描述：

  N-苄基哌啶酮 在 platinum on activated charcoal 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、2.07 MPa 条件下， 反应 22.58h， 生成 2-(1-苄基-4-哌啶)乙腈
  参考文献：
  名称：

  基于多奈哌齐和埃布塞林融合的抗阿尔茨海默氏病多靶标配体的合成和评价

  摘要：

  通过将胆碱酯酶抑制剂多奈哌齐和抗氧化剂依布硒啉融合获得的一系列新化合物被设计为针对阿尔茨海默氏病的多靶标配体。体外测定表明，这些分子中的某些分子没有表现出强效的胆碱酯酶抑制活性，但确实具有与依布硒仑相关的各种其他药理作用。在这些分子中，发现化合物7d是最有效的乙酰胆碱酯酶抑制剂之一（电泳电乙酰胆碱酯酶的IC 50值为0.042μM，人乙酰胆碱酯酶的IC 50值为0.097μM），是一种强丁酰胆碱酯酶抑制剂（IC 50值为1.586μM），拥有快速的H 2 O 2和过氧亚硝酸盐清除活性，谷胱甘肽过氧化物酶样活性（ν 0 = 123.5μM分钟-1），并且是哺乳动物的TrxR的基板。小鼠毒性试验显示，剂量高达2000 mg / kg时无急性毒性。根据体外血脑屏障模型，7d能够穿透中枢神经系统。

  DOI：

  10.1021/jm401047q

文献信息

• 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04695575A1

  公开（公告）日：1987-09-22

  4-[(Bicyclic heterocyclyl)methyl and -hetero]-piperidines having antihistaminic and serotonin-antagonistic properties which compounds are useful agents in the treatment of allergic diseases.

  具有抗组胺和抗血清素特性的4-[(双环杂环基)甲基和-杂环]-哌啶类化合物在过敏疾病治疗中是有用的药物。
• Design, Synthesis, and Structure−Activity Relationships of a Series of 3-[2-(1-Benzylpiperidin-4-yl)ethylamino]pyridazine Derivatives as Acetylcholinesterase Inhibitors
  作者：Jean-Marie Contreras、Isabelle Parrot、Wolfgang Sippl、Yveline M. Rival、Camille G. Wermuth

  DOI：10.1021/jm001088u

  日期：2001.8.1

  Starting from the 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-6-phenylpyridazine 1, we performed the design, the synthesis, and the structure-activity relationships of a series of pyridazine analogues acting as AChE inhibitors. Structural modifications were achieved on four different parts of compound 1 and led to the following observations: (i) introduction of a lipophilic environment in the C-5 position

  从3- [2-（1-苄基哌啶-4-基）乙基氨基] -6-苯基哒嗪1开始，我们进行了一系列作为AChE抑制剂的哒嗪类似物的设计，合成和结构-活性关系。在化合物1的四个不同部分进行了结构修饰，得出以下结论：（i）在哒嗪环的C-5位引入亲脂性环境有利于AChE抑制活性和AChE / BuChE选择性; （ii）C-6苯基的取代和各种取代是可能的，并导致等同或稍微活性更高的衍生物；（iii）苄基哌啶部分的等排取代或修饰对活性是有害的。在所有准备好的衍生物中，茚并哒嗪衍生物4g被发现是更有效的抑制剂，在电鳗AChE上的IC（50）为10 nM。与化合物1相比，其效力提高了12倍。此外，IC [50]为21 nM的3- [2-（1-苄基哌啶-4-基）乙基氨基] -5-甲基-6-苯基哒嗪4c对人AChE的选择性高100倍（人BuChE / AChE之比为24）比参比他克林。
• Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives
  作者：Hachiro Sugimoto、Yutaka Tsuchiya、Hiroyuki Sugumi、Kunizo Higurashi、Norio Karibe、Yoichi Iimura、Atsushi Sasaki、Yoshiyuki Kawakami、Takaharu Nakamura

  DOI：10.1021/jm00169a008

  日期：1990.7

  to play an important role in the increased activity, since the N-benzoylpiperidine derivative was almost inactive. We found that 1-benzyl-4-[2-(N-[4'-(benzylsulfonyl) benzoyl]-N-methylamino]ethyl]piperidine hydrochloride (21) (IC50 = 0.56 nM) is one of the most potent inhibitors of acetylcholinesterase. Compound 21 showed an affinity 18,000 times greater for AChE than for BuChE. At a dose of 3 mg/kg

  合成了一系列的1-苄基-4- [2-（N-苯甲酰基氨基）乙基]哌啶衍生物，并评估了其抗乙酰胆碱酯酶（anti-AChE）的活性。用对位上的大体积部分取代苯甲酰胺导致活性显着增加。在苯甲酰胺的氮原子上引入烷基或苯基大大增强了活性。哌啶氮原子的基本质量似乎在活性增加中起重要作用，因为N-苯甲酰基哌啶衍生物几乎没有活性。我们发现1-苄基-4- [2-（N- [4'-（苄基磺酰基）苯甲酰基] -N-甲基氨基]乙基]哌啶盐酸盐（21）（IC50 = 0.56 nM）是最有效的抑制剂之一化合物21对AChE的亲和力比对BuChE的亲和力大18,000倍，剂量为3 mg / kg时，21在大鼠的脑涡和海马中产生了乙酰胆碱（ACh）含量的显着显着增加。选择化合物21作为抗痴呆剂进行高级开发。
• Anti-histaminic benzimidazole, imidazopyridine and purine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04943580A1

  公开（公告）日：1990-07-24

  Novel 1-alkyl substituted benzimidazole derivatives and their pharmaceutically acceptable acid addition salts having anti-histaminic properties, compositions containing the same, and methods of treating allergic diseases in warm-blooded animals.

  新型1-烷基取代苯并咪唑衍生物及其药用可接受的酸盐，具有抗组胺作用，含有这些衍生物的组合物，以及治疗温血动物过敏疾病的方法。
• 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04254127A1

  公开（公告）日：1981-03-03

  Novel 1,3-dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives which compounds are potent serotonin-antagonists and central nervous system depressants, having utility as antiemetic, neuroleptic and anti-congestive agents.

  新型1,3-二氢-1-[(1-哌啶基)烷基]-2H-苯并咪唑-2-酮衍生物，这些化合物是有效的5-羟色胺拮抗剂和中枢神经系统抑制剂，具有作为抗恶心、神经阻滞剂和抗充血剂的用途。

表征谱图